Granted Patent
B2
US 12,447,166 · App. 15/691,648 · Granted Oct 21, 2025
Compositions and methods for protecting against airborne pathogens and irritants
Assignee:
APPLIED BIOLOGICAL LABORATORIES, INC.
A61K31/7012A61K9/0019A61K9/0043A61K9/0073A61K31/352A61K31/7016A61K33/30A61K33/34A61K33/38A61K36/28A61K36/328A61K36/53A61K36/752A61K38/1774A61K38/40A61K38/47A61K45/06A61K47/10A61K47/26A61K47/44A61P11/00A61P31/00C12Y302/01017C12N9/24C12N2760/16263
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation or ingestion of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses.
Claims (17)
1. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or excipients, a first active agent that is ICAM-1, and a second active agent that is a combination of lactoferrin and lysozyme;
wherein said composition is in the form of a nasal spray, nasal drops, oral spray, oral rinse, or lozenge having a suitable viscosity to possess a residence time on the mucosa of the nasal or oral cavities of at least 1 minute; and
said first and second active agents are present in said composition in individual form,
the weight ratio of said first active agent to said second active agent is about 1:100 to about 1:200 and
the weight ratio of lactoferrin to lysozyme is about 1:4 to about 1:20.
2. The pharmaceutical composition according to claim 1 , further comprising one or more of zinc peroxide, copper, and silver.
3. The pharmaceutical composition according to claim 1 , further comprising carrageenan.
4. The pharmaceutical composition according to claim 1 , further comprising one or more ingredients selected from the group consisting of marshmallow extract, Calendula extract, citrus peel extract, honey extract, rosemary extract, myrrh extract, Helichrysum extract, arrowroot extract, neem oil, vitamin C, vitamin E, and grapefruit seed extract.
5. The pharmaceutical composition according to claim 1 , wherein the composition is a lozenge.
6. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 0.0000001% to 0.1% soluble ICAM-1 by weight of the composition.
7. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 0.000001% to 0.01% soluble ICAM-1 by weight of the composition.
8. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 0.0000001-1.0% soluble lactoferrin by weight of the composition.
9. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 0.000001-1.0% lysozyme by weight of the composition.
10. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises
from about 0.000001% to 0.01% soluble ICAM-1 by weight of the composition,
from about 0.0000001-1.0% soluble lactoferrin by weight of the composition, and
from about 0.000001-1.0% lysozyme by weight of the composition.
Assignments (3)
SECURITY INTEREST
Recorded Mar 4, 2026
From: APPLIED BIOLOGICAL LABORATORIES INC.
To: TRANSMINEO LLC
Reel/Frame 074779/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 30, 2024
From: LATEFI, NAZLIE, MRS.
To: APPLIED BIOLOGICAL LABORATORIES, INC.
Reel/Frame 068129/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 25, 2017
From: LATEFI, NAZLIE
To: APPLIED BIOLOGICAL LABORATORIES, INC.
Reel/Frame 043988/0307 →
Continuity (3)
Provisional Application
62299755
· Feb 25, 2016
References Cited (116)
US 2156254A
· Manchey
· 1939
[cited by examiner]
US 4734279A
· Wolfgang et al.
· 1988
[cited by applicant]
US 5576299A
· Ando et al.
· 1996
[cited by applicant]
US 5993809A
· Weaver et al.
· 1999
[cited by applicant]
US 6017880A
· Eisenberg et al.
· 2000
[cited by applicant]
US 6020333A
· Berque
· 2000
[cited by applicant]
US 6093417A
· Petrus
· 2000
[cited by examiner]
US 6183742B1
· Kiczka
· 2001
[cited by applicant]
US 6329339B1
· Pompei et al.
· 2001
[cited by applicant]
US 6365156B1
· Lee
· 2002
[cited by examiner]
US 6503881B2
· Krieger et al.
· 2003
[cited by applicant]
US 6716813B2
· Lim et al.
· 2004
[cited by applicant]
US 7459283B2
· Wertz et al.
· 2008
[cited by applicant]
US 7662607B2
· Wang et al.
· 2010
[cited by applicant]
US 7846430B2
· Ferrari
· 2010
[cited by applicant]
US 7989003B2
· Hensley et al.
· 2011
[cited by applicant]
US 8263138B2
· Perraudin
· 2012
[cited by applicant]
US 20010006939A1
· Niven et al.
· 2001
[cited by applicant]
US 20030134779A1
· Diarra et al.
· 2003
[cited by applicant]
US 20030219402A1
· Rutter
· 2003
[cited by examiner]
US 20040248825A1
· McCullers
· 2004
[cited by applicant]
US 20050158327A1
· Mohapatra et al.
· 2005
[cited by applicant]
US 20060159671A1
· Fischetti
· 2006
[cited by applicant]
US 20070099855A1
· Cinatl
· 2007
[cited by applicant]
US 20070116750A1
· Wolcott
· 2007
[cited by applicant]
US 20080131454A1
· Grassauer
· 2008
[cited by examiner]
US 20090142298A1
· Shatunovskiy
· 2009
[cited by applicant]
US 20100143490A1
· Roberts et al.
· 2010
[cited by applicant]
US 20100209419A1
· Bhushan
· 2010
[cited by examiner]
US 20110015120A1
· Bortolin
· 2011
[cited by applicant]
US 20110059919A1
· Grassauer et al.
· 2011
[cited by applicant]
US 20110182857A1
· Watts
· 2011
[cited by examiner]
US 20120171164A1
· Wittke et al.
· 2012
[cited by applicant]
US 20120308579A1
· Tobin
· 2012
[cited by applicant]
US 20130028882A1
· Colman
· 2013
[cited by examiner]
US 20130034542A1
· Ganter et al.
· 2013
[cited by applicant]
US 20130309220A1
· Matalon
· 2013
[cited by applicant]
US 20140121237A1
· Tripp
· 2014
[cited by applicant]
CN 100493605C
· 2009
[cited by applicant]
CN 101947278A
· 2011
[cited by applicant]
CN 101966285B
· 2013
[cited by applicant]
EP 2845606A1
· 2015
[cited by applicant]
GB 981260A
· 1965
[cited by applicant]
GB 1171183A
· 1969
[cited by applicant]
GB 1174187A
· 1969
[cited by applicant]
GB 1431709
· 1976
[cited by applicant]
GB 1431709A
· 1976
[cited by applicant]
GB 2374008B
· 2005
[cited by applicant]
KR 101119538B1
· 2012
[cited by applicant]
KR 20120065654A
· 2012
[cited by applicant]
RU 2504396C1
· 2014
[cited by applicant]
RU 2535053C2
· 2014
[cited by applicant]
RU 2548803C2
· 2015
[cited by applicant]
WO 09527736A1
· 1995
[cited by applicant]
WO 9527736
· 1995
[cited by applicant]
WO 1998006425A1
· 1998
[cited by applicant]
WO 0012081A1
· 2000
[cited by applicant]
WO WO0032171A2
· 2000
[cited by examiner]
WO 2001092336A1
· 2001
[cited by applicant]
WO 03051281A2
· 2003
[cited by applicant]
WO 2004024919A1
· 2004
[cited by applicant]
WO 2006028497A2
· 2006
[cited by applicant]
WO WO2009009156A2
· 2009
[cited by examiner]
WO 201107367A2
· 2011
[cited by applicant]
WO 2015092047A2
· 2015
[cited by applicant]
WO 2017147540A1
· 2017
[cited by applicant]
Carvalho et al. (Abstract—44th Annual Meeting of the Brazilian Society for Biochemistry and Molecular Biology, Aug. 2015, p. 1 (Year: 2015).
[cited by examiner]
Greve et al. (Journal of Virology, Nov. 1991. p. 6015-6023). (Year: 1991).
[cited by examiner]
Jake Dunning, et al, Antiviral Combinations for Severe Influenza, 14 Lancet Infect. Dis. 1259 (Year: 2014).
[cited by examiner]
Tesia Bobrowski, et al, Synergistic and Antagonistic Drug Combinations against SARS-COV-2, 29 Mol. Ther. 873 (Year: 2021).
[cited by examiner]
Gabriella Cisani, et al, Inhibition of Herpes Simplex Virus-Induced Cytopathic Effect by Modified Hen Egg-white Lysozymes, 10 Curr. Microbiol. 35 (Year: 1984).
[cited by examiner]
Rodolfo Ferrari, et al, Antiviral Activity of Lysozyme, 183 Nature 548 (Year: 1959).
[cited by examiner]
U. Gluck, Zur Antimikrobiellen Wirkung von Lysozym aug der Nasenschleimhaut (in vivo tests of lysozyme of the nasal mucosa), 37 HNO 207 (Year: 1989).
[cited by examiner]
Sylvia Lee-Huang, et al, Lysozyme and RNases as anti-HIV Components in B-core Preparations of Human Chorionic Gonadotropin, 96 Proc. Natl. Acad. Sci. USA (Year: 1999).
[cited by examiner]
Wieslaw Kopec, et al, Activity of Protease Inhibitors and Lysozyme of Hen's Egg White Depending on Feed Modification and Egg Storage, 15 Pol. J Food Nutr. Sci (Year: 2005).
[cited by examiner]
Abigail Rae Berkebile, Airway Surface Liquid Antiviral Activity in Cystic Fibrosis, University of Iowa Master's Thesis, Jul. 2015 (available at https://doi.org/10.17077/etd.ssuamajh) (Year: 2015).
[cited by examiner]
Ronald J. Tallarida, Quantitative Methods for Assessing Drug Synergism, 2 Genes & Cancer 1003 (Year: 2011).
[cited by examiner]
G. Lampis, et al, Enhancement of Anti-Herpetic Activity of Glycyrrhizic Acid by Physiological Proteins, 12 Antivir. Chenm. Chemother. 125 (Year: 2001).
[cited by examiner]
Antonio Pellegrini & Monika Engels, Antiviral Compounds Derived from Naturally Occurring Proteins, 4 Curr. Med. Chem.—Anti-Infective Agents, 55 (Year: 2005).
[cited by examiner]
JM Davis et al, “Quercentin reduces susceptibility to influenza infection following stressful exercise,” Am J Physiol Regul Integr Comp Physiol 295 (2008):R505-R509.
[cited by applicant]
AA Al-Nabulsi et al, “Enhancing the antimicrobial effects of bovine lactoferrin against
[cited by applicant]
H Wakabayashi et al, “Lactoferrin for prevention of common viral infections” J Infect Chemoter 20 (2014): 666-671.
[cited by applicant]
SD Marlin “A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection” Nature 344 (1990): 70.
[cited by applicant]
Y Kim “Inhibition of influenza virus replication by plant-derived isoquercetin” Antiviral Research 88 (2010): 227-235.
[cited by applicant]
Written Opinion and International Search Report for PCT/US17/19535.
[cited by applicant]
Written Opinion and International Search Report for PCT/US18/48544.
[cited by applicant]
Written Opinion and International Search Report for PCT/US18/48985.
[cited by applicant]
K Saad et al., “Effects of bovine colostrum on recurrent respiratory tract infections and diarrhea in children” Medicine 95 (2016): 37.
[cited by applicant]
J Muscedere “Prevention of nosocomial infections in critically ill patients with lactoferrin (PREVAIL study): study protocol for a randomized controlled trial” Trials 17 (2016): 474.
[cited by applicant]
A Abouhmad et al., “T4 lysozyme fused with cellulose-binding module for antimicrobial cellulosic wound dressing materials” Journal of Applied Microbiology 121 (2016): 115-125.
[cited by applicant]
Pammi M et al., “Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates (Review)” The Cochrane Library 10 (2011).
[cited by applicant]
YH Samaranayake et al., “Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces” Archives of Oral Biology 54 (2009): 115-126.
[cited by applicant]
W Lei “Dynamic Spongy Microporous Films to Load Lysozyme for Antibacterial Coating” Acta Polymerica Sinica 5 (2017): 750-751.
[cited by applicant]
Wakabayashi et al., “Lactoferrin for prevention of common viral infections,” Journal of Infection and Chemotherapy, Aug. 30, 2014, vol. 20, 666-671.
[cited by applicant]
Al-Nabulsi et al., “Enhancing the antimicrobial effects of bovine lactoferrin against
[cited by applicant]
Davis et al., “Quercetin reduces susceptibility to influenza infection following stressful exercise,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, Aug. 1, 2008, vol. 295 R505-R509.
[cited by applicant]
Kim et al., Inhibition of influenza virus replication by plant-derived isoquercetin, Antiviral Research, Aug. 31, 2010, vol. 88, 227-235.
[cited by applicant]
Saad et al., “Effects of bovine colostrum on recurrent respiratory tract infections and diarrhea in children,” Medicine, vol. 95, issue 37, pp. 1-5 (2016).
[cited by applicant]
Abouhmad et al., “T4 lysozyme fused with cellulos-binding module for antimicrobial cellulosic wound dressing materials,” Journal of Applied Microbiology, vol. 121, pp. 115-125 (2016).
[cited by applicant]
International Search Report and Written Opinion to corresponding International Application No. PCT/US2017/019535 mailed May 8, 2017 (12 pages).
[cited by applicant]
Lei et al., “Dynamic Spongy Microporous Films to Load Lysozyme for Antibacterial Coating,” Acta Polymerica Sinica, No. 5, pp. 744-751 (2017).
[cited by applicant]
Marlin et al., “A Soluble Form of Intercellular Adhesion Molecule-1 Inhibits Rhinovirus Infection,” Nature; London, vol. 344, No. 6261, pp. 70-72 (1990).
[cited by applicant]
Muscedere et al., “Prevention of nosocomial infections in critically ill patients with lactoferrin (PREVAIL study): study protocol for a randomized controlled trial,” Trials, vol. 17, No. 474 (2016).
[cited by applicant]
Pammi et al., “Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates (Review),” Issue 10, 14 pages (2011).
[cited by applicant]
Samaranayake et al., “Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces,” ScienceDirect, vol. 54, pp. 115-126 (2009).
[cited by applicant]
Search Report for corresponding Russian Patent Application No. 2018133581 (2 pages).
[cited by applicant]
Office Action for corresponding Russian Patent Application No. 2018133581, issued on Aug. 11, 2020 (5 pages).
[cited by applicant]
Yulish, et al., “Factors of immunity in respiratory infections and methods for their activating in aid of a pediatrist,” 2010, vol. 5, No. 6, pp. 63-67 (English Abstract).
[cited by applicant]
Communication Pursuant to Article 94(3) in Corresponding EP App No. 17757390.4, issued Mar. 16, 2021.
[cited by applicant]
First Examination Report for corresponding Indian Application No. 201817032360, dated Jun. 25, 2020 (6 pages).
[cited by applicant]